Education
About Us
Working with TipRanks
Follow Us
Entero Therapeutics (ENTO)
NASDAQ:ENTO
Total Valuation
Entero Therapeutics has a market cap or net worth of $9.38M. The enterprise value is ―.
Market Cap$9.38M
Enterprise Value―
Share Statistics
Entero Therapeutics has 3,361,903 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,361,903
Owned by Insiders1.09%
Owned by Institutions―
Financial Efficiency
Entero Therapeutics’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -0.03%.
Return on Equity (ROE)-0.31
Return on Assets (ROA)-0.21
Return on Invested Capital (ROIC)-0.03%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee0.00
Profits Per Employee-9.03M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Entero Therapeutics is ―. Entero Therapeutics’s PEG ratio is 0.00525.
PE Ratio―
PS Ratio0.00
PB Ratio0.15
Price to Fair Value0.15
Price to FCF-0.94
Price to Operating Cash Flow-2.43
PEG Ratio0.00525
Income Statement
In the last 12 months, Entero Therapeutics had revenue of 0.00 and earned -18.06M in profits. Earnings per share was -3.88.
Revenue0.00
Gross Profit0.00
Operating Income―
Pretax Income―
Net Income-18.06M
EBITDA―
Earnings Per Share (EPS)-3.88
Cash Flow
In the last 12 months, operating cash flow was -1.90M and capital expenditures 0.00, giving a free cash flow of -1.90M billion.
Operating Cash Flow-1.90M
Free Cash Flow-1.90M
Free Cash Flow per Share-0.57
Dividends & Yields
Entero Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.63
52-Week Price Change52.05%
50-Day Moving Average3.78
200-Day Moving Average2.27
Relative Strength Index (RSI)41.20
Average Volume (3m)123.51K
Important Dates
Entero Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Entero Therapeutics as a current ratio of 3.03, with Debt / Equity ratio of 3.00%
Current Ratio3.03
Quick Ratio3.03
Debt to Market Cap0.00
Net Debt to EBITDA-0.69
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Entero Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate<0.01
Enterprise Valuation
Entero Therapeutics EV to EBITDA ratio is 260.41, with an EV/FCF ratio of -0.94.
EV to Sales0.00
EV to EBITDA260.41
EV to Free Cash Flow-0.94
EV to Operating Cash Flow-0.94
Balance Sheet
Entero Therapeutics has $2.52M in cash and marketable securities with $835.61K in debt, giving a net cash position of $1.68M billion.
Cash & Marketable Securities$2.52M
Total Debt$835.61K
Net Cash$1.68M
Net Cash Per Share$0.50
Tangible Book Value Per Share$12.06
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Entero Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―